Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H16O8 |
| Molecular Weight | 408.3576 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C(C1=C(O)C2=C(OC1=O)C=CC=C2)C3=C(O)C4=C(OC3=O)C=CC=C4
InChI
InChIKey=JCLHQFUTFHUXNN-UHFFFAOYSA-N
InChI=1S/C22H16O8/c1-2-28-20(25)15(16-18(23)11-7-3-5-9-13(11)29-21(16)26)17-19(24)12-8-4-6-10-14(12)30-22(17)27/h3-10,15,23-24H,2H2,1H3
| Molecular Formula | C22H16O8 |
| Molecular Weight | 408.3576 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14885082
Curator's Comment: Tromexan was synthesized by von Reinis and Kubik in 1948.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q9BQB6 Gene ID: 79001.0 Gene Symbol: VKORC1 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Tromexan Approved UseThromboses, thrombophlebitis, pulmonary embolisms, thromboembolic episodes at a myocardial infarction, heart failure. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
40.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8351679/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: TRISILOXANE |
ETHYL BISCOUMACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
31 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8351679/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETHYL BISCOUMACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7874379/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETHYL BISCOUMACETATE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.03 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7874379/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
7-HYDROXY ETHYL BISCOUMACETATE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://go.drugbank.com/drugs/DB08794 |
yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Serious surgical complications associated with chronic anticoagulant therapy]. | 2001-06 |
|
| Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease. | 1996-06-21 |
|
| [Effect of protein synthesis inhibitors on the vicasol-induced change in the content of the thermostable antifactor Xa in the blood serum]. | 1980-01-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13057879
The initial dosage was 900 to 1,800 mg (usually 1,200 or 1,500 mg). The subsequent dosage was judged by daily prothrombin time determinations. Daily maintenance dosage ranged from 300 to 900 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7203295
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:59:20 GMT 2025
by
admin
on
Wed Apr 02 09:59:20 GMT 2025
|
| Record UNII |
08KL644731
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
B01AA08
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
||
|
WHO-VATC |
QB01AA08
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
||
|
NCI_THESAURUS |
C263
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
||
|
EPA PESTICIDE CODE |
11901
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
325
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY | |||
|
1091
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY | |||
|
208-940-5
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY | |||
|
m5095
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY | Merck Index | ||
|
C75157
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY | |||
|
D005017
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY | |||
|
SUB07285MIG
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY | |||
|
100000082601
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY | |||
|
Ethyl biscoumacetate
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY | |||
|
548-00-5
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY | |||
|
CHEMBL81697
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY | |||
|
54685524
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY | |||
|
36366
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY | |||
|
DB08794
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY | |||
|
DTXSID3057771
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY | |||
|
08KL644731
Created by
admin on Wed Apr 02 09:59:20 GMT 2025 , Edited by admin on Wed Apr 02 09:59:20 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |